Malmström H, Carstensen J, Simonsen E
Department of Gynecologic Oncology, University Hospital, Linköping, Sweden.
Gynecol Oncol. 1994 Jul;54(1):27-34. doi: 10.1006/gyno.1994.1161.
Peritoneal access devices (port-catheters) were subcutaneously implanted in 125 patients for intraperitoneal chemotherapy of ovarian cancer. In 98% of patients Pharmacia's Port-A-Cath was used. Four hundred sixty-five intraperitoneal courses were given to these patients, with a median of 4 courses per patient (range 0-8). The first course was given 0-60 days (median 11 days) after Port-A-Cath implantation. In 125 patients, 27 (21.6%) complications of severe or moderate degree during the treatment were registered. In 81% of the patients, the treatment was given according to chemotherapy protocol as outlined. In 7% of the patients, early termination was related to the use of Port-A-Cath and in 12% related to chemotherapy. The probability for proper functioning of Port-A-Cath was 0.74 at 6 months and 0.69 at 1 year after implantation. The mean observation time was 13.6 months, median 10.5 (range 0.3-59.6 months). Total patient access time was 141.9 years. In conclusion, the complication rate after implantation of intraperitoneal access devices is acceptable. The rate of infections associated with the system is lower than that associated with open catheter systems.
在125例卵巢癌患者中皮下植入了腹膜接入装置（端口导管）用于腹腔内化疗。98%的患者使用了法玛西亚公司的Port-A-Cath。这些患者共接受了465个腹腔疗程的治疗，每位患者的中位数为4个疗程（范围为0 - 8个疗程）。第一个疗程在Port-A-Cath植入后0 - 60天（中位数为11天）进行。125例患者中，有27例（21.6%）在治疗期间出现了严重或中度并发症。81%的患者按照概述的化疗方案进行治疗。7%的患者早期终止治疗与Port-A-Cath的使用有关，12%与化疗有关。Port-A-Cath植入后6个月时正常运作的概率为0.74，1年时为0.69。平均观察时间为13.6个月，中位数为10.5个月（范围为0.3 - 59.6个月）。患者总的接入时间为141.9年。总之，腹腔接入装置植入后的并发症发生率是可以接受的。与该系统相关的感染率低于与开放式导管系统相关的感染率。
